` OABI (OmniAb Inc) vs S&P 500 Comparison - Alpha Spread

OABI
vs
S&P 500

Over the past 12 months, OABI has underperformed S&P 500, delivering a return of -61% compared to the S&P 500's 8% growth.

Stocks Performance
OABI vs S&P 500

Loading

Performance Gap
OABI vs S&P 500

Loading
OABI
S&P 500
Difference

Performance By Year
OABI vs S&P 500

Loading
OABI
S&P 500
Add Stock

Competitors Performance
OmniAb Inc vs Peers

S&P 500
OABI
0KHE
TMO
DHR
207940
Add Stock

OmniAb Inc
Glance View

Market Cap
214m USD
Industry
Life Sciences Tools & Services

OmniAb, Inc. operates as a drug discovery company. The company is headquartered in Emeryville, California and currently employs 93 full-time employees. The company went IPO on 2020-10-09. The OmniAb platform is the biological intelligence (BI) of transgenic animals, including OmniRat, OmniChicken, and OmniMouse, which have been genetically modified to generate antibodies with human sequences to facilitate the development of human therapeutic candidates. Its OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications through a common light chain approach and OmniTaur features structural attributes of cow antibodies for complex targets. The firm's OmniChicken and OmniClic offer affinity-matured antibodies in an evolutionarily distant chicken host environment, which can deliver a diverse repertoire of antibody panels to conserved therapeutic targets.

OABI Intrinsic Value
1.38 USD
Overvaluation 22%
Intrinsic Value
Price
O
Back to Top